艾司西酞普兰与舍曲林对伴焦虑症状的抑郁症患者的效果和安全性比较

Efficacy and safety of escitalopram and sertraline in the treatment of depression patients with anxiety symptoms

目的比较艾司西酞普兰与舍曲林对伴焦虑症状的抑郁症患者的疗效和安全性。方法纳入2018年1月~2020年12月的66例抑郁症伴焦虑症状患者,遵循随机数字表法将病例分配至对照组(纳入33例,行舍曲林治疗)、观察组(纳入33例,行艾司西酞普兰治疗),评价组间汉密尔顿焦虑量表(Hamilton Anxiety Scale,HAMA)、汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)、治疗有效率、用药安全性。结果(1)治疗前,组间HAMA、HAMD无差异,P>0.05;治疗4周后,观察组HAMA、HAMD较低,P<0.05,但是治疗8周后组间的HAMA、HAMD无差异,P>0.05;(2)在治疗有效率方面,观察组(90.91%)与对照组(87.88%)无差异,P>0.05;(3)观察组胃肠道反应(3.03%)、头痛(3.03%)、静坐不能(0.00%)发生率低于对照组(18.18%)、(27.27%)、(12.12%),P<0.05,但是组间嗜睡、失眠发生率无差异,P>0.05。结论艾司西酞普兰、舍曲林均能有效治疗抑郁症伴焦虑症状患者,但前者见效快、不良反应少。

Objective To evaluate the efficacy and safety of escitalopram and sertraline in the treatment of depression with anxiety symptoms.Methods 66 patients with depression and anxiety symptoms from january2018 to December 2020 were included.The patients were randomly assigned to the control group(33 patients were included and treated with sertraline)and the observation group(33 patients were included and treated with escitalopram).The Hamilton Anxiety Scale(HAMA),Hamilton Depression Scale(HAMD),treatment efficiency and safety were compared beween two groups.Results(1)Before treatment,there was no difference in HAMA and HAMD between two groups,P>0.05.After 4 weeks of treatment,HAMA and HAMD in the observation group were lower(P<0.05),but there was no difference in HAMA and HAMD between two groups after 8 weeks of treatment(P>0.05).(2)There was no difference in rats of efficiency between the observation group(90.91%)and the control group(87.88%),P>0.05.(3)The incidence of gastrointestinal reaction(3.03%),headache(3.03%),and inability to sit still(0.00%)in the observation group was lower than that in the control group(18.18%),(27.27%)and(12.12%),P<0.05,but there was no difference in the incidence of sleepiness and insomnia between the groups(P>0.05).Conclusion Both escitalopram and sertraline can effectively treat depression patients with anxiety symptoms,but the former has quick effect and less adverse reactions.